Avalon GloboCare to Ring the Nasdaq Stock Market Closing Bell on January 7, 2019 at 4:00 PM Eastern
December 19 2018 - 8:00AM
Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global
developer of cell-based technologies and therapeutics, today
announced that it will ring The Nasdaq Stock Market Closing Bell at
the Nasdaq MarketSite in Times Square at 4:00 PM Eastern time,
Monday, January 7, 2019. A live webcast of The Nasdaq Stock Market
Closing Bell ceremony will be available at:
https://new.livestream.com/nasdaq/live.
David Jin, M.D., Ph.D., President and CEO of
Avalon GloboCare, stated, “We are honored to ring the closing bell
at the Nasdaq MarketSite in celebration of our recent listing. We
are rapidly advancing a variety of cell-based therapies,
particularly within the field of CAR-T cell therapy, while
leveraging our proprietary exosome technology platform and
aggressively expanding within the regenerative medicine market. I
would like to thank our employees, investors and partners for all
the ongoing support, which has been invaluable to our success, and
we look forward to driving value for shareholders in the months and
years ahead.”
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: AVCO) is a
global intelligent biotech developer and healthcare service
provider dedicated to promoting and empowering high impact,
transformative cell-based /technologies and their clinical
applications, as well as healthcare facility management through its
core platforms, namely "Avalon Cell" and "Avalon Rehab." In
addition, Avalon provides strategic advisory and outsourcing
services to facilitate and enhance their clients' growth,
development, as well as competitiveness in both domestic and global
healthcare markets. Avalon also engages in the management of stem
cell banks and specialty clinical laboratories. Through its U.S.
subsidiaries, namely GenExosome Technologies Inc. and Avactis
Biosciences Inc., Avalon will further establish our leading roles
in the fields of CAR-T therapy, liquid biopsy, precision medicine
and regenerative medicine.
Forward-Looking Statements
Certain statements contained in this press
release may constitute "forward-looking
statements." Forward-looking statements provide current
expectations of future events based on certain assumptions and
include any statement that does not directly relate to any
historical or current fact. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors as disclosed in our filings with the
Securities and Exchange Commission located at their website
(http://www.sec.gov). In addition to these factors, actual future
performance, outcomes, and results may differ materially because of
more general factors including (without limitation) general
industry and market conditions and growth rates, economic
conditions, and governmental and public policy changes. The
forward-looking statements included in this press release represent
the Company's views as of the date of this press release and these
views could change. However, while the Company may elect to update
these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing the Company's views as of any date subsequent to the
date of the press release.
Contact Information: Avalon GloboCare
Corp. 4400 Route 9, Suite 3100 Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations: Crescendo Communications,
LLC Tel: (212) 671-1020 avco@crescendo-ir.com
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avalon GloboCare (NASDAQ:AVCO)
Historical Stock Chart
From Apr 2023 to Apr 2024